Overview

ACT-TIL and ANV419 for Advanced Melanoma.

Status:
Not yet recruiting

Trial end date:
2025-06-01

Target enrollment:

Participant gender:

Summary

In this study we aim to investigate safety and tolerability of tumor-infiltrating lymphocytes (TIL) adoptive cell therapy (ACT) incorporation in-vivo TIL expansion with ANV419 in patients with advanced melanoma

Phase:

Phase 1

Details

Lead Sponsor:

University Hospital, Basel, Switzerland

Collaborator:

Anaveon AG